Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: Activity against SARS-CoV-2 and Potential Mechanisms
AuthorPuhl, Ana C
Fritch, Ethan J
Lane, Thomas R
Tse, Longping V
Yount, Boyd L
Sacramento, Carolina Q
Tavella, Tatyana Almeida
Maranhão Costa, Fabio Trindade
Pearce, Kenneth H
Hurst, Brett L
Andrade, Carolina Horta
Levi, James A
Johnson, Nicole J
Kisthardt, Samantha C
Souza, Thiago Moreno L
Moorman, Nathaniel John
Baric, Ralph S
Madrid, Peter B
PublisherAmerican Chemical Society
MetadataShow full item record
AbstractSevere acute respiratory coronavirus 2 (SARS-CoV-2) is a newly identified virus that has resulted in over 2.5 million deaths globally and over 116 million cases globally in March, 2021. Small-molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown in vitro activity against Ebola viruses and demonstrated activity against SARS-CoV-2 in vivo. Most notably, the RNA polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans. Testing other small-molecule drugs that are active against Ebola viruses (EBOVs) would appear a reasonable strategy to evaluate their potential for SARS-CoV-2. We have previously repurposed pyronaridine, tilorone, and quinacrine (from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of Ebola and Marburg viruses in vitro in HeLa cells and mouse-adapted EBOV in mice in vivo. We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7, and monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively. We used microscale thermophoresis to test the binding of these molecules to the spike protein, and tilorone and pyronaridine bind to the spike receptor binding domain protein with Kd values of 339 and 647 nM, respectively. Human Cmax for pyronaridine and quinacrine is greater than the IC50 observed in A549-ACE2 cells. We also provide novel insights into the mechanism of these compounds which is likely lysosomotropic.
Rights/Terms© 2021 The Authors. Published by American Chemical Society.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15138
- Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.
- Authors: Puhl AC, Fritch EJ, Lane TR, Tse LV, Yount BL, Sacramento CQ, Tavella TA, Costa FTM, Weston S, Logue J, Frieman M, Premkumar L, Pearce KH, Hurst BL, Andrade CH, Levi JA, Johnson NJ, Kisthardt SC, Scholle F, Souza TML, Moorman NJ, Baric RS, Madrid P, Ekins S
- Issue date: 2020 Dec 2
- Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
- Authors: Lane TR, Ekins S
- Issue date: 2020 Aug 13
- Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.
- Authors: Lane TR, Dyall J, Mercer L, Goodin C, Foil DH, Zhou H, Postnikova E, Liang JY, Holbrook MR, Madrid PB, Ekins S
- Issue date: 2020 Oct
- Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.
- Authors: Lane TR, Massey C, Comer JE, Freiberg AN, Zhou H, Dyall J, Holbrook MR, Anantpadma M, Davey RA, Madrid PB, Ekins S
- Issue date: 2020 Sep
- Machine learning models identify molecules active against the Ebola virus <i>in vitro</i>.
- Authors: Ekins S, Freundlich JS, Clark AM, Anantpadma M, Davey RA, Madrid P
- Issue date: 2015